$CYAB

CYABRA, INC. (CYAB): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

CYABRA, INC. (CYAB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Adoption of an amendment to the 2026 Omnibus Equity Incentive Plan On September 2, 2026, Cyabra, Inc. (the “ Company ”) hel

Original reporting
Published Sep 3, 2026, 1:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 1:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CYAB
Neutral
medium confidence
Mentioned
$CYAB
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CYABNeutralLow
01

Why it matters

The amendment increases the maximum shares issuable and sets an annual reserve of 15% of fully diluted shares, which could affect share count and compensation strategy.

02

Market read

Primary corporate action for a micro‑cap; limited broader market effect.

03

What to watch

Potential for accelerated hiring and growth initiatives enabled by the larger equity pool.

Relevance 6/10Novelty 5/10Timing: filing day

Background

CYAB filed an 8‑K detailing a shareholder‑approved amendment to its equity incentive plan.

Company-level read

Ticker impact

$CYABNeutralMedium confidence
Context

SEC 8‑K reports amendment to CYAB's 2026 Omnibus Equity Incentive Plan increasing share reserve.

Expected impact

Potential short‑term price pressure from dilution concerns, long‑term neutral to slightly positive if compensation drives growth.

Evidence & confidence

Dilution is modest relative to market cap; impact depends on future hires and performance.

Market effects

Minimal impact on broader tech sector; similar plan amendments are common.

Limited to US micro‑cap market.

Low

Counterpoint

Investors may view the dilution as a catalyst for a sell‑off.

Key entities

  • Cyabra, Inc.

    Issuer of the 8‑K filing.

  • Dan Brahmy

    Chief Executive Officer who signed the filing.

Related articles

$CYABMedAI 8/10

Cyabra Delivers Record Second Quarter Revenue with 39% Year-Over-Year Growth

Cyabra, Inc. (Nasdaq: CYAB) reported record Q2 2026 revenue of $1.9 million, up 39% year over year from $1.3 million, driven mainly by new customer wins and higher existing-customer revenue. Gross margin stayed about 84%. The company also cited a $500,000+ research institute agreement, new government and intelligence customers, and a $6.0 million private placement.

$CYABMedAI 8/10

Cyabra Announces Pricing of $6.0 Million Private Placement Priced At a Premium to the Market Price with New and Existing Institutional Investors, Management, and Board Members

Cyabra, Inc. (Nasdaq: CYAB) priced a $6.0 million private placement to sell 13,818,770 shares plus Series A and Series B warrants at $0.435 per share. Series A warrants exercise at $0.50 and expire five years; Series B exercise at $0.45 and expire 12 months, both subject to stockholder approval. Preferred shares will convert to common or equivalents, pending approval.